Precise targeting and controlled drug release can significantly enhance the therapeutic efficacy of cancer treatment. Trackable smart drug delivery systems have gained attention in the past decade because they can be visualised by one or more imaging technologies through their distinct physical properties. However, it is still difficult to achieve precise drug delivery because such systems usually rely on a single imaging system that cannot clearly distinguish the drug carrier system from the surrounding tissue and the targeted lesion.
Avacta Group Plc (LON:AVCT) principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
